Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
8 studies found for:    "Riociguat (BAY63-2521)"
Show Display Options
Rank Status Study
1 Withdrawn Coronary Vasomotor Response After Riociguat Exposure
Condition: Coronary Artery Disease
Intervention: Drug: Riociguat (BAY63-2521)
2 Recruiting EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension
Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat(BAY63-2521)
3 Active, not recruiting BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat (BAY63-2521)
4 Terminated A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction
Conditions: Hypertension, Pulmonary;   Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (BAY63-2521);   Drug: Placebo
5 Terminated Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
Condition: Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Interventions: Drug: Adempas, Riociguat (BAY63-2521);   Device: Placebo
6 Completed Relative Bioavailability and Food Effect Study
Condition: Pharmacology, Clinical
Intervention: Drug: Riociguat (BAY63-2521)
7 Terminated
Has Results
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
Conditions: Hypertension, Pulmonary;   Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo
8 Active, not recruiting
Has Results
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Conditions: Hypertension, Pulmonary;   Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.